Orforglipron: a Step Forward Toward Simplifying Management of Obesity and Type 2 Diabetes
Clinical Research and Clinical Trials · 17.02.2026 · 15 (02) · 01-04
DOI: 10.31579/2693-4779/314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research and Clinical Trials, online erschienen am 17.02.2026. Verfasst von Nasser Mikhail * und 1 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Orforglipron is a non-peptide agonist of glucagon-like peptide-1 (GLP-1) receptor that is administered orally once-daily independent of food intake. Currently, orforglipron is under clinical development for treatment of obesity and type 2 diabetes. Three phase 3 double-blind clinical trials were recently published to evaluate efficacy and safety of orforglipron in subjects with obesity and type 2 diabetes. In individuals with obesity, mean percent weight loss at 72 weeks was -11.2% with the highest dose of orforglipron (36 mg/d) compared with -2.1% with placebo. Weight loss reached its peak after 48 weeks of intervention followed by a plateau. In patients with early type 2 diabetes, orforglipron 36 mg/d was associated with reduction of glycated hemoglobin (HbA1c) values of -1.48% versus -0.41% with placebo at 40 weeks. Discontinuation rates due to adverse effects were 5-10% with orforglipron versus 1.4-5% with placebo. Most adverse effects were gastrointestinal (GI) occurring mainly during dose escalation. Increased diabetic retinopathy with orforglipron emerged as a safety signal in one trial despite excluding patients with baseline diabetic retinopathy. In patients with type 2 diabetes, preliminary data from the ACHIEVE-3 trial suggest that orforglipron is superior to oral semaglutide in terms of glycemic control and weight loss, but drug discontinuation rates due to adverse effects are double those recorded with oral semaglutide. Overall, orforglipron is a promising GLP-1 receptor agonist characterized by its simplicity of administration. Its long-term efficacy and safety require further investigations in a broader spectrum of subjects with obesity and type 2 diabetes.
Zitieren
APA
*, N. M., & Wali, S. (2026). Orforglipron: a Step Forward Toward Simplifying Management of Obesity and Type 2 Diabetes. Clinical Research and Clinical Trials, 15(02), 01-04. https://doi.org/10.31579/2693-4779/314
Vancouver
* NM, Wali S. Orforglipron: a Step Forward Toward Simplifying Management of Obesity and Type 2 Diabetes. Clinical Research and Clinical Trials. 2026;15(02):01-04. doi:10.31579/2693-4779/314
BibTeX
@article{2026,
author = {*, Nasser Mikhail and Wali, Soma},
title = {Orforglipron: a Step Forward Toward Simplifying Management of Obesity and Type 2 Diabetes},
journal = {Clinical Research and Clinical Trials},
year = {2026},
volume = {15},
number = {02},
pages = {01--04},
doi = {10.31579/2693-4779/314}
}
EUVIMED